Últimas noticias sobre ChromaDex (NASDAQ:CDXC) Bolsa

ChromaDex

ChromaDex Corp is a bioscience company dedicated to healthy aging. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen. The company has three reportable segments namely Consumer Products, Ingredients segment, and Analytical Reference Standards and Services. The majority of the revenue is earned from the Consumer Products segment.

ChromaDex Corp

Ladenburg Thalmann analyst Jeffrey Cohen maintains ChromaDex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) with a Buy and raises the price target from $6.8 to $8.1.

News

Price Target

Analyst Ratings

CDXC

Ladenburg Thalmann Maintains Buy on ChromaDex, Raises Price Target to $8.1

WIIM

ChromaDex shares are trading higher after the company reported better-than-expected Q4 financial results and FY25 revenue guidance above estimates.

Earnings

Guidance

ChromaDex Sees FY25 18% Revenue Growth YoY.

ChromaDex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) reported quarterly earnings of $0.09 per share which beat the analyst consensus estimate of $0.02 by 350 percent. The company reported quarterly sales of $29.125 million which beat the analyst consensus estimate of $26.733 million by 8.95 percent. This is a 37.41 percent increase over sales of $21.196 million the same period last year.

Earnings Beats

ChromaDex Q4 2024 GAAP EPS $0.09 Beats $0.02 Estimate, Sales $29.125M Beat $26.733M Estimate

<h3>Companies Reporting Before The Bell</h3>
• 908 Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASS#NASDAQ">MASS</a>) is likely to report quarterly loss at $0.37 per share on revenue of $16.18 million. 
• Plug Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>) is projected to report quarterly loss at $0.23 per share on revenue of $262.65 million. 
• NexGen Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NXE#NYSE">NXE</a>) is projected to report earnings for its fourth quarter. 
• EVgo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGO#NASDAQ">EVGO</a>) is estimated to report quarterly loss at $0.09 per share on revenue of $69.00 million. 
• L.B. Foster (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSTR#NASDAQ">FSTR</a>) is estimated to report quarterly earnings at $0.22 per share on revenue of $131.48 million. 
• WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) is estimated to report quarterly loss at $0.24 per share on revenue of $25.59 million. 
• InfuSystems Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INFU#AMEX">INFU</a>) is projected to report quarterly earnings at $0.08 per share on revenue of $34.40 million. 
• Amylyx Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMLX#NASDAQ">AMLX</a>) is expected to report earnings for its fourth quarter. 
• Neuronetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STIM#NASDAQ">STIM</a>) is projected to report quarterly loss at $0.24 per share on revenue of $18.98 million. 
• Y-mAbs Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) is estimated to report quarterly loss at $0.12 per share on revenue of $26.94 million. 
• Olaplex Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLPX#NASDAQ">OLPX</a>) is projected to report quarterly earnings at $0.01 per share on revenue of $87.51 million. 
• Hagerty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HGTY#NYSE">HGTY</a>) is expected to report quarterly earnings at $0.01 per share on revenue of $279.58 million. 
• Angel Oak Mortgage REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AOMR#NYSE">AOMR</a>) is expected to report quarterly earnings at $0.27 per share on revenue of $9.99 million. 
• Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) is estimated to report quarterly loss at $0.13 per share on revenue of $63.06 million. 
• Sophia Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOPH#NASDAQ">SOPH</a>) is expected to report quarterly loss at $0.15 per share on revenue of $17.71 million. 
• Paysafe (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSFE#NYSE">PSFE</a>) is projected to report quarterly earnings at $0.72 per share on revenue of $437.22 million. 
• Compugen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGEN#NASDAQ">CGEN</a>) is likely to report quarterly loss at $0.07 per share on revenue of $24.96 million. 
• Sea (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SE#NYSE">SE</a>) is expected to report quarterly earnings at $0.70 per share on revenue of $4.60 billion. 
• Genius Sports (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GENI#NYSE">GENI</a>) is estimated to report quarterly earnings at $0.07 per share on revenue of $175.71 million. 
• On Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONON#NYSE">ONON</a>) is expected to report quarterly earnings at $0.18 per share on revenue of $593.34 million. 
• Nayax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NYAX#NASDAQ">NYAX</a>) is projected to report quarterly earnings at $0.10 per share on revenue of $91.89 million. 
• Best Buy Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>) is likely to report quarterly earnings at $2.42 per share on revenue of $13.69 billion. 
• Target (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) is likely to report quarterly earnings at $2.65 per share on revenue of $30.28 billion. 
• CPI Card (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMTS#NASDAQ">PMTS</a>) is estimated to report quarterly earnings at $0.57 per share on revenue of $118.97 million. 
• Wag Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PET#NASDAQ">PET</a>) is likely to report quarterly earnings at $0.40 per share on revenue of $290.88 million. 
• Modiv Industrial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDV#NYSE">MDV</a>) is expected to report quarterly earnings at $0.27 per share on revenue of $11.86 million. 
• AutoZone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZO#NYSE">AZO</a>) is estimated to report quarterly earnings at $29.90 per share on revenue of $4.00 billion. 
<h3>Companies Reporting After The Bell</h3>
• Medallion Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MFIN#NASDAQ">MFIN</a>) is expected to report quarterly earnings at $0.33 per share on revenue of $53.66 million. 
• Southland Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SLND#AMEX">SLND</a>) is projected to report quarterly loss at $0.49 per share on revenue of $230.13 million. 
• Gulf Island Fabrication (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIFI#NASDAQ">GIFI</a>) is expected to report quarterly earnings at $0.12 per share on revenue of $41.00 million. 
• Cumberland (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPIX#NASDAQ">CPIX</a>) is projected to report earnings for its fourth quarter. 
• Baytex Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTE#NYSE">BTE</a>) is estimated to report quarterly earnings at $0.16 per share on revenue of $980.40 million. 
• Stellus Cap Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>) is estimated to report quarterly earnings at $0.39 per share on revenue of $26.54 million. 
• ChromaDex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) is estimated to report quarterly earnings at $0.02 per share on revenue of $26.52 million. 
• Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) is expected to report quarterly earnings at $0.33 per share on revenue of $57.60 million. 
• Astronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRO#NASDAQ">ATRO</a>) is likely to report quarterly earnings at $0.28 per share on revenue of $194.91 million. 
• Fuel Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTEK#NASDAQ">FTEK</a>) is expected to report quarterly loss at $0.03 per share on revenue of $5.63 million. 
• comScore (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCOR#NASDAQ">SCOR</a>) is likely to report quarterly earnings at $0.36 per share on revenue of $91.66 million. 
• Alpha Teknova (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TKNO#NASDAQ">TKNO</a>) is estimated to report quarterly loss at $0.12 per share on revenue of $8.78 million. 
• Mayville Engineering (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MEC#NYSE">MEC</a>) is projected to report quarterly loss at $0.08 per share on revenue of $124.13 million. 
• NeuroPace (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NPCE#NASDAQ">NPCE</a>) is estimated to report quarterly loss at $0.24 per share on revenue of $21.11 million. 
• ATN International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNI#NASDAQ">ATNI</a>) is projected to report quarterly loss at $0.19 per share on revenue of $179.11 million. 
• Stem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STEM#NYSE">STEM</a>) is projected to report quarterly loss at $0.16 per share on revenue of $49.37 million. 
• OrthoPediatrics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIDS#NASDAQ">KIDS</a>) is projected to report quarterly loss at $0.26 per share on revenue of $52.70 million. 
• Ascent Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACNT#NASDAQ">ACNT</a>) is expected to report earnings for its fourth quarter. 
• Ecopetrol (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EC#NYSE">EC</a>) is estimated to report quarterly earnings at $0.41 per share on revenue of $7.68 billion. 
• Horizon Tech Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRZN#NASDAQ">HRZN</a>) is projected to report quarterly earnings at $0.32 per share on revenue of $25.68 million. 
• Owlet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OWLT#NYSE">OWLT</a>) is expected to report quarterly loss at $0.48 per share on revenue of $16.92 million. 
• AeroVironment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAV#NASDAQ">AVAV</a>) is expected to report quarterly earnings at $0.86 per share on revenue of $214.00 million. 
• Ross Stores (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>) is estimated to report quarterly earnings at $1.67 per share on revenue of $5.95 billion. 
• Evolus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOLS#NASDAQ">EOLS</a>) is likely to report quarterly earnings at $0.00 per share on revenue of $77.23 million. 
• Eos Energy Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOSE#NASDAQ">EOSE</a>) is expected to report quarterly loss at $0.20 per share on revenue of $6.23 million. 
• CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) is expected to report quarterly loss at $0.31 per share on revenue of $58.79 million. 
• Ingram Micro Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INGM#NYSE">INGM</a>) is likely to report quarterly earnings at $0.90 per share on revenue of $13.22 billion. 
• ChargePoint Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHPT#NYSE">CHPT</a>) is likely to report quarterly loss at $0.07 per share on revenue of $100.97 million. 
• Credo Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NASDAQ">CRDO</a>) is estimated to report quarterly earnings at $0.18 per share on revenue of $120.31 million. 
• Crexendo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CXDO#NASDAQ">CXDO</a>) is expected to report quarterly earnings at $0.05 per share on revenue of $15.64 million. 
• CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) is estimated to report quarterly earnings at $0.86 per share on revenue of $1.03 billion. 
• Ooma (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OOMA#NYSE">OOMA</a>) is likely to report quarterly earnings at $0.16 per share on revenue of $64.70 million. 
• Custom Truck One Source (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTOS#NYSE">CTOS</a>) is expected to report quarterly earnings at $0.05 per share on revenue of $539.81 million. 
• Cricut (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRCT#NASDAQ">CRCT</a>) is expected to report quarterly earnings at $0.04 per share on revenue of $214.41 million. 
• Orion Gr Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORN#NYSE">ORN</a>) is estimated to report quarterly earnings at $0.19 per share on revenue of $272.70 million. 
• Latham Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWIM#NASDAQ">SWIM</a>) is likely to report quarterly loss at $0.01 per share on revenue of $84.95 million. 
• Box (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOX#NYSE">BOX</a>) is estimated to report quarterly earnings at $0.41 per share on revenue of $278.60 million. 
• Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>) is projected to report quarterly earnings at $0.91 per share on revenue of $223.23 million. 
• Weyco Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEYS#NASDAQ">WEYS</a>) is projected to report earnings for its fourth quarter. 
• Sociedad Quimica Y Minera (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQM#NYSE">SQM</a>) is likely to report quarterly earnings at $0.84 per share on revenue of $1.13 billion. 
• Nordstrom (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JWN#NYSE">JWN</a>) is likely to report quarterly earnings at $0.90 per share on revenue of $4.33 billion. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACNT

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

AOMR

ATNI

ATRO

AVAV

CGEN

CHPT

CPIX

CRCT

CRDO

CRWD

CTOS

CXDO

CYRX

EOLS

EOSE

ESPR

EVGO

FSTR

FTEK

GENI

GIFI

HGTY

HRZN

INFU

INGM

KIDS

MASS

MFIN

NPCE

Nuveen Arizona Dividend Advantage Municipal Funds 3

NYAX

OLPX

ONON

OOMA

OWLT

PLUG

PMTS

PSFE

RIGL

ROST

SCOR

SLND

SOPH

STEM

STIM

SWIM

TKNO

WEYS

YMAB

Earnings Scheduled For March 4, 2025

U.S. stock futures were higher this morning, with the Dow futures gaining more than 300 points on Monday.
Shares of Cassava Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>) fell sharply in today's pre-market trading after the company announced Simufilam did not show a significant reduction in cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer&#8217;s disease in the ReThink-ALZ <a href="https://www.benzinga.com/quote/SAVA">Phase 3 study</a>.
Cassava Sciences shares dipped 85.6% to $3.82 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Centessa Pharmaceuticals PLC – ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTA#NASDAQ">CNTA</a>) shares tumbled 12% to $15.00 in pre-market trading after falling 6% on Friday. On Nov. 12, Centessa Pharmaceuticals reported a quarterly loss of 37 cents per share.</li>
<li>Biohaven Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHVN#NYSE">BHVN</a>) fell 11% to $40.60 in pre-market trading after the company announced its treatment arm of the RESILIENT SMA study did not statistically separate on the primary outcome at Week 48 compared to the placebo+standard of care group.</li>
<li>ZIM Integrated Shipping Services Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>) shares dipped 6.9% to $22.15 in pre-market trading. ZIM Integrated Shipping Services, last week, reported better-than-expected third-quarter financial results and raised its FY24 adjusted EBIT and EBITDA guidance.</li>
<li>i3 Verticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IIIV#NASDAQ">IIIV</a>) shares declined 6.6% to $22.11 in pre-market trading. The company, last week, posted downbeat quarterly results.</li>
<li>ChromaDex Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) fell 5.9% to $7.00 in pre-market trading.</li>
<li>Fitell Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTEL#NASDAQ">FTEL</a>) shares declined 4.9% to $24.00 in pre-market trading after gaining around 6% on Friday.</li>
<li>Logility Supply Chain Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGTY#NASDAQ">LGTY</a>) fell 4.4% to $9.31 in pre-market trading. Logility Supply Chain Solutions shares dipped 13% on Friday after the company reported worse-than-expected second-quarter revenue results and issued FY25 revenue guidance below estimates.</li>
<li>Kingsoft Cloud Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KC#NASDAQ">KC</a>) fell 4.3% to $6.90 in today's pre-market trading after jumping around 25% on Friday. Kingsoft Cloud, last week, reported a fiscal third-quarter 2024 revenue of 1.89 billion Chinese yuan ($268.7 million), up by 16.0% year-on-year, beating the analyst consensus estimate of $247.46 million</li>
</ul>
Now Read This: 
<a href="https://www.benzinga.com/24/11/42157664/zoom-video-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call">Zoom Video Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a>

Pre-Market Outlook

Markets

Movers

Trading Ideas

BHVN

CNTA

FTEL

IIIV

LGTY

SAVA

Cassava Sciences, Biohaven And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Shares of Uxin Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UXIN#NYSE">UXIN</a>) rose sharply in today's pre-market trading after the company reported <a href="https://www.benzinga.com/quote/UXIN/earnings">second-quarter financial results.</a>
Uxin posted quarterly sales of $70.85 million, up from $48.80 million in the year-ago period
Uxin shares rose 3% to $6.50 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Rigetti Computing, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) gained 59.2% to $2.77 in pre-market trading after climbing around 18% on Friday.</li>
<li>Quantum Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QMCO#NASDAQ">QMCO</a>) rose 40.4% to $12.84 in pre-market trading after jumping 127% on Friday.</li>
<li>KULR Technology Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KULR#NYSE">KULR</a>) gained 29.8% to $0.5777 in pre-market trading after gaining around 7% on Friday.</li>
<li>Exicure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) gained 28.4% to $23.59 in pre-market trading after jumping around 69% on Friday.</li>
<li>Arqit Quantum Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQQ#NASDAQ">ARQQ</a>) gained 22% to $15.76 in pre-market trading after gaining 21% on Friday.</li>
<li>NOVONIX Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVX#NASDAQ">NVX</a>) gained 19.1% to $2.31 in pre-market trading. Novonix secured a 32,000-tonne offtake agreement with Volkswagen&#8217;s PowerCo for synthetic graphite supply.</li>
<li>Quantum Computing Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) gained 16.9% to $7.13 in pre-market trading after jumping 28% on Friday.  </li>
<li>Allot Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLT#NASDAQ">ALLT</a>) climbed 16.7% to $4.94 in pre-market trading. Allot, last week, reported better-than-expected quarterly financial results.</li>
<li>Lionsgate Studios Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LION#NASDAQ">LION</a>) gained 11.2% to $7.89 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Akoustis Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKTS#NASDAQ">AKTS</a>) shares tumbled 37.5% to $0.0629 in pre-market trading</li>
<li>Aptose Biosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) shares fell 17.8% to $0.1560 in pre-market trading. Aptose Biosciences shares dipped 22% on Friday after the company announced the pricing of an $8 million public offering.</li>
<li>X3 Holdings Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTKG#NASDAQ">XTKG</a>) declined 16.6% to $1.76 in pre-market trading.</li>
<li>NewGenIvf Group Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) fell 16.1% to $0.43 in pre-market trading after declining 6% on Friday.</li>
<li>Elevai Labs Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELAB#NASDAQ">ELAB</a>) fell 13.9% to $0.0173 in pre-market trading. Elevai Labs implemented a 1-for-200 reverse stock split to retain Nasdaq listing, reducing shares to 3.07 million.</li>
<li>Gold Resource Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GORO#NYSE">GORO</a>) shares fell 13.1% to $0.1368 in pre-market trading after gaining 6% on Friday.</li>
<li>Digital Brands Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBGI#NASDAQ">DBGI</a>) dipped 12.4% to $0.1063 in pre-market trading after falling over 4% on Friday.</li>
<li>ZIM Integrated Shipping Services Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>) shares dipped 6.9% to $22.15 in pre-market trading. ZIM Integrated Shipping Services, last week, reported better-than-expected third-quarter financial results and raised its FY24 adjusted EBIT and EBITDA guidance.</li>
<li>ChromaDex Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) fell 5.9% to $7.00 in pre-market trading.</li>
<li>Kingsoft Cloud Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KC#NASDAQ">KC</a>) fell 4.3% to $6.90 in today's pre-market trading after jumping around 25% on Friday. Kingsoft Cloud, last week, reported a fiscal third-quarter 2024 revenue of 1.89 billion Chinese yuan ($268.7 million), up by 16.0% year-on-year, beating the analyst consensus estimate of $247.46 million</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42137942/jim-cramer-says-this-stock-is-a-bitcoin-play-and-he-prefers-to-own-bitcoin">Jim Cramer Says This Stock Is A Bitcoin Play And He Prefers To Own Bitcoin</a></li>
</ul>

AKTS

ALLT

APTO

ARQQ

DBGI

ELAB

GORO

KULR

LION

NIVF

Nuveen California Dividend Advantage Municipal Fund 2

QMCO

QUBT

RGTI

UXIN

XCUR

XTKG

Why Uxin Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

Rumors

Watching ChromaDex; Traders Circulate Stock Picked By Zacks Under $10 Newsletter

National rollout provides enhanced accessibility to Niagen IV, a significant advancement in NAD+ IV therapy
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.chromadex.com%2F&amp;esheet=54148595&amp;newsitemid=20241107717521&amp;lan=en-US&amp;anchor=ChromaDex+Corp.&amp;index=1&amp;md5=da63f1d6565b279efe182d481f9f4417">ChromaDex Corp.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, today announced the nationwide rollout of its pharmaceutical-grade nicotinamide riboside chloride (NRC) products, <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.restore.com%2Fservices%2Fniagen-nr-iv-drips&amp;esheet=54148595&amp;newsitemid=20241107717521&amp;lan=en-US&amp;anchor=Niagen%26%23174%3B+IV&amp;index=2&amp;md5=4e4a198d6bc02d3a8a0436866bc0bf99">Niagen&#xAE; IV</a>, now accessible at over 200 <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.restore.com%2F&amp;esheet=54148595&amp;newsitemid=20241107717521&amp;lan=en-US&amp;anchor=Restore+Hyper+Wellness&amp;index=3&amp;md5=b92ab7ac903e69534f009fafba60c504">Restore Hyper Wellness</a> locations across the United States. This represents a major milestone, making Niagen IV—a significant advancement in intravenous NAD+ therapy—more widely accessible to wellness enthusiasts looking to enhance cellular health and extend their healthspan.
Available in oral and IV forms, ChromaDex's clinically proven patented ingredient, Niagen, is the most efficient, high-quality NAD+ precursor available. NAD+ is a coenzyme that powers cells and supports metabolic processes throughout the body, yet it declines with age and due to everyday stressors like sun exposure, high-fat diets, overtraining, and sedentary lifestyles—a decline linked to both age-related and other health conditions.
The IV formulations support the rapid and efficient delivery of Niagen. Outperforming NAD+ IV in the pilot clinical study, Niagen IV offered superior tolerability, a 75% shorter infusion time, and resulted in a statistically significant 20% increase in whole blood NAD+ levels three hours post-infusion, as measured by NAD+ dried blood spot tests (<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.1101%2F2024.06.06.24308565v1&amp;esheet=54148595&amp;newsitemid=20241107717521&amp;lan=en-US&amp;anchor=MedRxiv&amp;index=4&amp;md5=c02307f45e41c3b66a691e7904e0ad4a">MedRxiv</a>).

Biotech

General

ChromaDex's Pharmaceutical-Grade Niagen IV Now Accessible At Over 200 Restore Hyper Wellness Clinics Nationwide

ChromaDex shares are trading higher after Roth MKM maintained a Buy rating on the stock and raised its price target from $6 to $8.

Roth MKM analyst Sean McGowan maintains ChromaDex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) with a Buy and raises the price target from $6 to $8.

Roth MKM Maintains Buy on ChromaDex, Raises Price Target to $8

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains ChromaDex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) with a Buy and raises the price target from $6 to $8.

HC Wainwright & Co. Maintains Buy on ChromaDex, Raises Price Target to $8

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 100 points on Friday.
The Dow traded up 0.67% to 42,043.38 while the NASDAQ surged 0.75% to 18,230.53. The S&amp;P 500 also rose, gaining, 0.47% to 5,732.21.
Check This Out: <a href="https://www.benzinga.com/news/24/10/41653495/top-2-real-estate-stocks-you-may-want-to-dump-this-quarter">Top 2 Real Estate Stocks You May Want To Dump This Quarter</a>
Leading and Lagging Sectors Consumer discretionary shares rose by 2.3% on Friday.
In trading on Friday, utilities shares fell by 2.1%.
Top Headline
Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) shares fell around 2% on Friday after the company reported results for the fourth quarter.
The company reported fiscal fourth-quarter revenue of $94.9 billion, beating analyst estimates of $94.56 billion. The iPhone maker reported fourth-quarter adjusted earnings of $1.64 per share, beating analyst estimates of $1.60 per share.
<h3 class="wp-block-heading">Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>ChromaDex Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) shares shot up 53% to $5.34 after the company reported a year-over-year increase in third-quarter EPS results and raised its FY24 revenue guidance.</li>
<li>Shares of Proto Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRLB#NASDAQ">PRLB</a>) got a boost, surging 33% to $36.42 after the company reported better-than-expected third-quarter financial results and issued fourth-quarter adjusted EPS guidance with its midpoint above estimates.</li>
<li>Interface, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TILE#NASDAQ">TILE</a>) shares were also up, gaining 33% to $23.23 after the company reported better-than-expected third-quarter financial results and raised its FY24 net sales guidance above estimates.</li>
</ul>
Equities Trading DOWN
<ul>
<li>ESSA Pharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EPIX#NASDAQ">EPIX</a>) shares dropped 71% to $1.51 after the company announced it terminated its Phase 2 study evaluating masofaniten combined with enzalutamide in patients with mCRPC.</li>
<li>Shares of Myriad Genetics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) were down 21% to $17.30. Myriad Genetics will hold its third quarter earnings conference call on Thursday, Nov. 7.</li>
<li>Lexicon Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) was down, falling 37% to $1.2250. Lexicon Pharmaceuticals announced the outcome of the FDA's Endocrinologic and Metabolic Drugs Advisory Committee Meeting to review the company's New Drug Application (NDA) for Zynquista (sotagliflozin). The company is seeking approval for the oral SGLT1/SGLT2 inhibitor as an adjunct to insulin therapy for glycemic control in adults with type 1 diabetes (T1D) and chronic kidney disease (CKD).</li>
</ul>
Commodities In commodity news, oil traded up 0.8% to $69.79 while gold traded down 0.1% at $2,745.60.
Silver traded down 0.7% to $32.555 on Friday, while copper rose 0.3% to $4.3520.
Euro zone
European shares were higher today. The eurozone's STOXX 600 gained 1.09%, Germany's DAX gained 0.93% and France's CAC 40 gained 0.80%. Spain's IBEX 35 Index surged 1.46%, while London's FTSE 100 rose 0.83%.
Asia Pacific Markets
Asian markets closed mostly lower on Friday, with Japan's Nikkei 225 falling 2.63%, Hong Kong's Hang Seng Index gaining 0.93%, China's Shanghai Composite Index declining 0.24% and India's BSE Sensex falling 0.27%.
Economics
<ul>
<li>The U.S. economy added 12,000 jobs in October compared to a revised 223,000 gain in September and versus market estimates of 113,000.</li>
<li>Average hourly earnings increased by 0.4% over a month to $35.46 in October, while unemployment rate came in unchanged at 4.1% in October.</li>
<li>U.S. construction spending increased by 0.1% month-over-month to an annual rate of $2,148.8 billion in September.</li>
<li>The S&amp;P Global Flash manufacturing PMI was revised upward to 48.5 in October versus a preliminary reading of 47.8.</li>
<li>The ISM manufacturing PMI declined to 46.5 in October versus 47.2 in the previous month and down from estimates of 47.6.</li>
<li>The total number of active U.S. oil rigs fell by one to 479 rigs this week, Baker Hughes Inc reported.</li>
</ul>
Now Read This: 
<ul>
<li><a href="Top%202%20Utilities%20Stocks%20That%20May%20Crash%20This%20Quarter">Top 2 Utilities Stocks That May Crash This Quarter</a></li>
</ul>

Equities

Eurozone

Commodities

AAPL

EPIX

LXRX

MYGN

PRLB

TILE

Crude Oil Moves Higher; Apple Shares Slide After Q4 Results

<h3>Gainers</h3>
<ul>
<li>Athira Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHA#NASDAQ">ATHA</a>) stock rose 50.3% to $0.64 during Friday's regular session. The market value of their outstanding shares is at $24.6 million. </li>
<li>ChromaDex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) shares increased by 45.55% to $5.08. The market value of their outstanding shares is at $385.7 million. The company's, Q3 earnings came out yesterday. </li>
<li>Theriva Biologics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#AMEX">TOVX</a>) shares rose 27.44% to $1.86. The company's market cap stands at $2.5 million. </li>
<li>GRI Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) shares rose 26.41% to $1.11. The company's market cap stands at $4.0 million. </li>
<li>Pro-Dex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) stock moved upwards by 25.53% to $38.94. The market value of their outstanding shares is at $130.7 million. The company's, Q1 earnings came out yesterday. </li>
<li>Pediatrix Medical Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MD#NYSE">MD</a>) stock increased by 20.73% to $14.88. The market value of their outstanding shares is at $1.2 billion. The company's, Q3 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Lexicon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) shares fell 35.1% to $1.26 during Friday's regular session. The market value of their outstanding shares is at $457.2 million. </li>
<li>Autonomix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) stock declined by 22.44% to $11.1. The market value of their outstanding shares is at $12.7 million. </li>
<li>Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) stock decreased by 21.57% to $17.23. The company's market cap stands at $1.5 billion. </li>
<li>Pulse Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLSE#NASDAQ">PLSE</a>) stock fell 14.0% to $14.99. The market value of their outstanding shares is at $918.7 million. The company's, Q3 earnings came out 2 days ago. </li>
<li>Biofrontera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRI#NASDAQ">BFRI</a>) shares decreased by 13.42% to $1.06. The company's market cap stands at $5.9 million. </li>
<li>Beyond Air (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAIR#NASDAQ">XAIR</a>) shares decreased by 12.38% to $0.5. The market value of their outstanding shares is at $36.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMIX

ATHA

BFRI

ALPS ETF Trusthen & Steers Global Realty Majors ETF

PDEX

PLSE

TOVX

XAIR

12 Health Care Stocks Moving In Friday's Intraday Session

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 200 points on Friday.
The Dow traded up 1.18% to 42,254.81 while the NASDAQ surged 1.31% to 18,332.35. The S&amp;P 500 also rose, gaining, 0.95% to 5,759.63.
Check This Out: <a href="https://www.benzinga.com/news/24/10/41653495/top-2-real-estate-stocks-you-may-want-to-dump-this-quarter">Top 2 Real Estate Stocks You May Want To Dump This Quarter</a>
Leading and Lagging Sectors Consumer discretionary shares rose by 2.9% on Friday.
In trading on Friday, utilities shares fell by 1.1%.
Top Headline
Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) shares surged 7% on Friday after the copany posted stronger-than-expected results for the third quarter.
Amazon reported third-quarter net sales of $158.9 billion, up 11% year-over-year. The total beat a Street consensus estimate of $157.2 billion, according to data from Benzinga Pro. The company said it sees fourth-quarter net sales to come in a range of $181.5 billion to $188.5 billion, up 7% to 11% year-over-year.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>ChromaDex Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) shares shot up 55% to $5.41 after the company reported a year-over-year increase in third-quarter EPS results and raised its FY24 revenue guidance.</li>
<li>Shares of Proto Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRLB#NASDAQ">PRLB</a>) got a boost, surging 31% to $36.54 after the company reported better-than-expected third-quarter financial results and issued fourth-quarter adjusted EPS guidance with its midpoint above estimates.</li>
<li>Interface, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TILE#NASDAQ">TILE</a>) shares were also up, gaining 33% to $23.15 after the company reported better-than-expected third-quarter financial results and raised its FY24 net sales guidance above estimates.</li>
</ul>
Equities Trading DOWN
<ul>
<li>ESSA Pharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EPIX#NASDAQ">EPIX</a>) shares dropped 70% to $1.58 after the company announced it terminated its Phase 2 study evaluating masofaniten combined with enzalutamide in patients with mCRPC.</li>
<li>Shares of Myriad Genetics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) were down 21% to $17.24. Myriad Genetics will hold its third quarter earnings conference call on Thursday, Nov. 7.</li>
<li>Lexicon Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) was down, falling 36% to $1.2550. Lexicon Pharmaceuticals announced the outcome of the FDA's Endocrinologic and Metabolic Drugs Advisory Committee Meeting to review the company's New Drug Application (NDA) for Zynquista (sotagliflozin). The company is seeking approval for the oral SGLT1/SGLT2 inhibitor as an adjunct to insulin therapy for glycemic control in adults with type 1 diabetes (T1D) and chronic kidney disease (CKD).</li>
</ul>
Commodities In commodity news, oil traded up 1.1% to $70.04 while gold traded up 0.2% at $2,753.70.
Silver traded down 0.1% to $32.755 on Friday, while copper rose 0.5% to $4.3635.
Euro zone
European shares were higher today. The eurozone's STOXX 600 gained 1.25%, Germany's DAX gained 1.10% and France's CAC 40 gained 1.05%. Spain's IBEX 35 Index surged 1.42%, while London's FTSE 100 rose 1.06%.
Asia Pacific Markets
Asian markets closed mostly lower on Friday, with Japan's Nikkei 225 falling 2.63%, Hong Kong's Hang Seng Index gaining 0.93%, China's Shanghai Composite Index declining 0.24% and India's BSE Sensex falling 0.27%.
Economics
<ul>
<li>The U.S. economy added 12,000 jobs in October compared to a revised 223,000 gain in September and versus market estimates of 113,000.</li>
<li>Average hourly earnings increased by 0.4% over a month to $35.46 in October, while unemployment rate came in unchanged at 4.1% in October.</li>
<li>U.S. construction spending increased by 0.1% month-over-month to an annual rate of $2,148.8 billion in September.</li>
<li>The S&amp;P Global Flash manufacturing PMI was revised upward to 48.5 in October versus a preliminary reading of 47.8.</li>
<li>The ISM manufacturing PMI declined to 46.5 in October versus 47.2 in the previous month and down from estimates of 47.6.</li>
</ul>
Now Read This: 
<ul>
<li><a href="Top%202%20Utilities%20Stocks%20That%20May%20Crash%20This%20Quarter">Top 2 Utilities Stocks That May Crash This Quarter</a></li>
</ul>

AMZN

Nasdaq Surges Over 200 Points; Amazon Shares Jump After Strong Results

U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 400 points on Friday.
The Dow traded up 1% to 42,182.88 while the NASDAQ surged 1.18% to 18,309.37. The S&amp;P 500 also rose, gaining, 0.98% to 5,761.25.
Check This Out: <a href="https://www.benzinga.com/news/24/10/41653495/top-2-real-estate-stocks-you-may-want-to-dump-this-quarter">Top 2 Real Estate Stocks You May Want To Dump This Quarter</a>
Leading and Lagging Sectors Consumer discretionary shares rose by 3.1% on Friday.
In trading on Friday, utilities shares fell by 0.1%.
Top Headline
The U.S. economy added 12,000 jobs in October compared to a revised 223,000 gain in September and versus market estimates of 113,000.
Average hourly earnings increased by 0.4% over a month to $35.46 in October, while unemployment rate came in unchanged at 4.1% in October.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>ChromaDex Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) shares shot up 55% to $5.38 after the company reported a year-over-year increase in third-quarter EPS results and raised its FY24 revenue guidance.</li>
<li>Shares of Proto Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRLB#NASDAQ">PRLB</a>) got a boost, surging 33% to $36.54 after the company reported better-than-expected third-quarter financial results and issued fourth-quarter adjusted EPS guidance with its midpoint above estimates.</li>
<li>Interface, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TILE#NASDAQ">TILE</a>) shares were also up, gaining 32% to $23.04 after the company reported better-than-expected third-quarter financial results and raised its FY24 net sales guidance above estimates.</li>
</ul>
Equities Trading DOWN
<ul>
<li>ESSA Pharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EPIX#NASDAQ">EPIX</a>) shares dropped 70% to $1.5450 after the company announced it terminated its Phase 2 study evaluating masofaniten combined with enzalutamide in patients with mCRPC.</li>
<li>Shares of Elevai Labs Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELAB#NASDAQ">ELAB</a>) were down 45% to $0.0325.</li>
<li>Lexicon Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) was down, falling 34% to $1.2790. Lexicon Pharmaceuticals announced the outcome of the FDA's Endocrinologic and Metabolic Drugs Advisory Committee Meeting to review the company's New Drug Application (NDA) for Zynquista (sotagliflozin). The company is seeking approval for the oral SGLT1/SGLT2 inhibitor as an adjunct to insulin therapy for glycemic control in adults with type 1 diabetes (T1D) and chronic kidney disease (CKD).</li>
</ul>
Commodities In commodity news, oil traded up 1.5% to $70.39 while gold traded up 0.4% at $2,761.30.
Silver traded up 0.3% to $32.890 on Friday, while copper rose 0.4% to $4.3575.
Euro zone
European shares were higher today. The eurozone's STOXX 600 gained 1%, Germany's DAX gained 0.8% and France's CAC 40 gained 0.7%. Spain's IBEX 35 Index surged 1.2%, while London's FTSE 100 rose 0.8%.
Asia Pacific Markets
Asian markets closed mostly lower on Friday, with Japan's Nikkei 225 falling 2.63%, Hong Kong's Hang Seng Index gaining 0.93%, China's Shanghai Composite Index declining 0.24% and India's BSE Sensex falling 0.27%.
Economics
<ul>
<li>The U.S. economy added 12,000 jobs in October compared to a revised 223,000 gain in September and versus market estimates of 113,000.</li>
<li>Average hourly earnings increased by 0.4% over a month to $35.46 in October, while unemployment rate came in unchanged at 4.1% in October.</li>
<li>U.S. construction spending increased by 0.1% month-over-month to an annual rate of $2,148.8 billion in September.</li>
<li>The S&amp;P Global Flash manufacturing PMI was revised upward to 48.5 in October versus a preliminary reading of 47.8.</li>
<li>The ISM manufacturing PMI declined to 46.5 in October versus 47.2 in the previous month and down from estimates of 47.6.</li>
</ul>
Now Read This: 
<ul>
<li><a href="Top%202%20Utilities%20Stocks%20That%20May%20Crash%20This%20Quarter">Top 2 Utilities Stocks That May Crash This Quarter</a></li>
</ul>

Dow Jumps 400 Points; US Adds 12,000 Jobs In October

<h3>Gainers</h3>
<ul>
<li>Envoy Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCH#NASDAQ">COCH</a>) shares increased by 66.0% to $4.4 during Friday's pre-market session. The company's market cap stands at $86.8 million. </li>
<li>Theriva Biologics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#AMEX">TOVX</a>) stock rose 43.83% to $2.1. The market value of their outstanding shares is at $2.8 million. </li>
<li>Athira Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHA#NASDAQ">ATHA</a>) shares rose 26.13% to $0.54. The market value of their outstanding shares is at $20.6 million. </li>
<li>Pro-Dex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) shares increased by 18.06% to $36.62. The company's market cap stands at $122.9 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Molecular Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOLN#NASDAQ">MOLN</a>) shares rose 16.79% to $6.26. The market value of their outstanding shares is at $230.5 million. </li>
<li>ChromaDex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) stock moved upwards by 16.04% to $4.05. The market value of their outstanding shares is at $307.5 million. As per the news, the Q3 earnings report came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Lexicon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) shares fell 39.5% to $1.18 during Friday's pre-market session. The market value of their outstanding shares is at $426.5 million. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) stock declined by 10.37% to $0.77. The company's market cap stands at $18.3 million. </li>
<li>Biofrontera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRI#NASDAQ">BFRI</a>) shares decreased by 9.76% to $1.11. The company's market cap stands at $6.1 million. </li>
<li>Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) stock declined by 9.1% to $1.6. The company's market cap stands at $15.1 million. </li>
<li>bioAffinity Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) stock fell 9.1% to $1.3. The market value of their outstanding shares is at $20.1 million. </li>
<li>Matinas BioPharma Hldgs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MTNB#AMEX">MTNB</a>) shares decreased by 8.07% to $0.57. The market value of their outstanding shares is at $2.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BIAF

Envoy Medical, Inc. - Class A Common Stock

COCH

MOLN

MTNB

ONMD

TRIB

12 Health Care Stocks Moving In Friday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Envoy Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCH#NASDAQ">COCH</a>) stock moved upwards by 66.0% to $4.4 during Friday's pre-market session. The market value of their outstanding shares is at $86.8 million. </li>
<li>Theriva Biologics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#AMEX">TOVX</a>) shares increased by 43.83% to $2.1. The company's market cap stands at $2.8 million. </li>
<li>Athira Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHA#NASDAQ">ATHA</a>) stock increased by 26.13% to $0.54. The company's market cap stands at $20.6 million. </li>
<li>Pro-Dex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) stock moved upwards by 18.06% to $36.62. The market value of their outstanding shares is at $122.9 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Molecular Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOLN#NASDAQ">MOLN</a>) stock rose 16.79% to $6.26. The company's market cap stands at $230.5 million. </li>
<li>ChromaDex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) shares increased by 16.04% to $4.05. The company's market cap stands at $307.5 million. As per the news, the Q3 earnings report came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Lexicon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) stock decreased by 39.5% to $1.18 during Friday's pre-market session. The market value of their outstanding shares is at $426.5 million. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) stock decreased by 10.37% to $0.77. The market value of their outstanding shares is at $18.3 million. </li>
<li>Biofrontera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRI#NASDAQ">BFRI</a>) shares declined by 9.76% to $1.11. The market value of their outstanding shares is at $6.1 million. </li>
<li>Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) shares fell 9.1% to $1.6. The company's market cap stands at $15.1 million. </li>
<li>bioAffinity Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) stock fell 9.1% to $1.3. The market value of their outstanding shares is at $20.1 million. </li>
<li>Matinas BioPharma Hldgs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MTNB#AMEX">MTNB</a>) stock declined by 8.07% to $0.57. The company's market cap stands at $2.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ChromaDex shares are trading higher after the company reported a year-over-year increase in Q3 EPS results and raised its FY24 revenue guidance.

<h3>Gainers</h3>
<ul>
<li>Athira Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHA#NASDAQ">ATHA</a>) stock rose 28.5% to $0.55 during Thursday's after-market session. The market value of their outstanding shares is at $21.0 million. </li>
<li>Theriva Biologics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#AMEX">TOVX</a>) shares increased by 28.08% to $1.87. The company's market cap stands at $2.5 million. </li>
<li>Pro-Dex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) shares increased by 19.69% to $37.13. The market value of their outstanding shares is at $124.6 million. </li>
<li>ChromaDex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) stock increased by 18.62% to $4.14. The market value of their outstanding shares is at $314.3 million. As per the news, the Q3 earnings report came out today. </li>
<li>Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) stock moved upwards by 7.7% to $54.49. The company's market cap stands at $6.9 billion. The company's, Q3 earnings came out today. </li>
<li>Ardelyx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARDX#NASDAQ">ARDX</a>) shares rose 7.49% to $6.31. The company's market cap stands at $1.4 billion. The company's, Q3 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Biofrontera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRI#NASDAQ">BFRI</a>) stock decreased by 10.6% to $1.1 during Thursday's after-market session. The company's market cap stands at $6.0 million. </li>
<li>BioRestorative Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRTX#NASDAQ">BRTX</a>) stock decreased by 5.74% to $1.47. The market value of their outstanding shares is at $10.1 million. </li>
<li>Palisade Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PALI#NASDAQ">PALI</a>) stock decreased by 5.52% to $2.57. The company's market cap stands at $3.0 million. </li>
<li>Innovative Eyewear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCY#NASDAQ">LUCY</a>) shares fell 5.49% to $7.75. The company's market cap stands at $18.6 million. </li>
<li>Ocean Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCEA#NASDAQ">OCEA</a>) shares fell 5.23% to $0.83. The company's market cap stands at $28.8 million. </li>
<li>Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) stock decreased by 5.12% to $1.67. The market value of their outstanding shares is at $15.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARDX

BRTX

HALO

LUCY

OCEA

PALI

12 Health Care Stocks Moving In Thursday's After-Market Session

Press Releases

ChromaDex to Participate in the 17th Annual LD Micro Main Event

ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024

ChromaDex Corporation Reports Third Quarter 2024 Financial Results

ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide

ChromaDex's Patented Nicotinamide Riboside (NR) Ingredient, Niagen®, Featured as the Hero Ingredient in Longevity.Technology's Inaugural Longevity Supplement

ChromaDex Named to the Inc. 2024 Best in Business List in the Health Products Category

ChromaDex to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

ChromaDex to Report Fourth Quarter and Fiscal Year 2024 Financial Results on Tuesday, March 4, 2025

ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 Results

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Atlantic International Corp. - Common Stock

Atlantic International

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solutions

Bruker

Codexis

Cytek Biosciences

CryoPort

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

ChromaDex

Noticias

Últimas noticias sobre ChromaDex (NASDAQ:CDXC) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL